2024
Telomere transcripts act as tumor suppressor and are associated with favorable prognosis in colorectal cancer with low proliferating cell nuclear antigen expression
Kienzl P, Deloria A, Hunjadi M, Hadolt J, Haering M, Bothien A, Mejri D, Korkut-Demirbaş M, Sampl S, Weber G, Pirker C, Laengle S, Braunschmid T, Dragona E, Marian B, Gagos S, Lu L, Henson J, Lau L, Reddel R, Mikulits W, Stättner S, Holzmann K. Telomere transcripts act as tumor suppressor and are associated with favorable prognosis in colorectal cancer with low proliferating cell nuclear antigen expression. Cellular Oncology 2024, 1-9. PMID: 39222177, DOI: 10.1007/s13402-024-00986-y.Peer-Reviewed Original ResearchSevere combined immunodeficiency diseaseTelomerase reverse transcriptaseProliferating cell nuclear antigenEpithelial-mesenchymal transitionColorectal cancerTelomerase RNA componentTumor tissuesTelomerase activityTelomeric repeat-containing RNAProliferating cell nuclear antigen expressionAssociated with favorable prognosisOverall survival rateCombined immunodeficiency diseaseTelomere lengthEpithelial splicing regulatory protein 1TERRA expressionColorectal cancer tumor tissuesCell nuclear antigenNon-canonical functions of telomerase reverse transcriptaseCRC tumor growthExpression levelsFavorable prognosisNon-tumor tissuesImmunodeficiency diseaseAdjacent non-tumor tissues
2014
The KRAS-Variant and miRNA Expression in RTOG Endometrial Cancer Clinical Trials 9708 and 9905
Lee LJ, Ratner E, Uduman M, Winter K, Boeke M, Greven KM, King S, Burke TW, Underhill K, Kim H, Boulware RJ, Yu H, Parkash V, Lu L, Gaffney D, Dicker AP, Weidhaas J. The KRAS-Variant and miRNA Expression in RTOG Endometrial Cancer Clinical Trials 9708 and 9905. PLOS ONE 2014, 9: e94167. PMID: 24732316, PMCID: PMC3986055, DOI: 10.1371/journal.pone.0094167.Peer-Reviewed Original ResearchConceptsEndometrial cancer riskType 2 endometrial cancerEndometrial cancerKRAS-variantCancer riskLymphovascular invasionSurvival outcomesTumor biologyType 1 endometrial cancerEndometrial cancer trialsOverall survival rateMiRNA expressionAge-matched controlsCase-control analysisFunctional germline variantsClinical characteristicsPatient ageTumor characteristicsCancer trialsTumor specimensSurvival rateType 1Germline variantsMiRNA expression levelsCancer